Vaccine Clinical Trial
Official title:
Immunity Against the COVID-19 Vaccine in Healthcare Workers of Buenos Aires, Argentine.
Vaccination against coronavirus disease 19 (COVID-19) is an essential primary prevention tool to limit the health and economic effects of the pandemic. Objectives: To determine the variation in the levels of Immunoglobulin G (IgG) antibodies in health workers who received a COVID-19 vaccine.
Vaccination against coronavirus disease 19 (COVID-19) is an essential primary prevention tool to limit the health and economic effects of the pandemic. The Ministry of Health of the Nation, designed the "Strategic Plan for vaccination", which the first line being the health workers " The National Administration of Medicines, Food and Medical Technology authorized two emergency vaccines for administration, Sputnik V and Sinopharm vaccine. It is important to evaluate immunogenicity and its correlation with the long-term efficacy and safety profile of this vaccines. Objectives: To determine the variation in the levels of Immunoglobulin G (IgG) antibodies in health workers who received a COVID-19 vaccine between the time before the first dose, and after 1 month, 6 months and 12 months after the completion of the immunization, depending on whether they have received the Sputnik V vaccine or the Sinopharm vaccine, and correlate the Immunoglobulin G levels with the presence of adverse events and infection with COVID-19 Methodology: Design: observational and analytical study of a prospective cohort of healthcare workers immunized with some COVID-19 vaccine. The presence of IgG will be determined qualitatively and quantitatively. The immunoglobulin G titer in each period will be compared globally and according to the type of vaccine administered. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
| Recruiting |
NCT04543877 -
WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study
|
Early Phase 1 | |
| Completed |
NCT00401505 -
Rubella Susceptibility in Multiparous Women
|
||
| Recruiting |
NCT05054621 -
Immunogenicity of COVID-19 Vaccine on Heterologous Schedule
|
Phase 2 | |
| Completed |
NCT05083065 -
Evaluation of Menstrual Irregularities and Abnormal Uterine Bleeding After Covid-19 Vaccine
|
||
| Recruiting |
NCT05085145 -
Immunogenicity and Safety of COVID-19 Vaccine in People Living With HIV
|
Phase 4 | |
| Completed |
NCT05046548 -
This is a Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19
|
Phase 1/Phase 2 | |
| Completed |
NCT01961947 -
Study of ASP7374, Cell-culture-derived Influenza Vaccine
|
Phase 3 | |
| Completed |
NCT01961960 -
A Study to Evaluate Intramuscular ASP7374
|
Phase 3 | |
| Completed |
NCT00401700 -
Influenza Vaccine Postpartum Questionnaire
|
||
| Completed |
NCT03300050 -
Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine
|
Phase 1 | |
| Completed |
NCT01015703 -
Open-label Safety and Tolerability Study of CoVaccine HT™ in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT00560066 -
Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions
|
Phase 4 | |
| Active, not recruiting |
NCT05099965 -
Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®)
|
Phase 2 | |
| Recruiting |
NCT04638985 -
Evaluation of Immunogenicity and Safety of Combined Immunization of sIPV, DTaP and MMR
|
Phase 4 | |
| Recruiting |
NCT06136832 -
Pneumonia Vaccine Education Intervention Study
|
N/A | |
| Active, not recruiting |
NCT04741828 -
Persistence and Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in Indonesian
|
Phase 2/Phase 3 | |
| Completed |
NCT05083039 -
Observational Program, Study the Preventive Efficacy of the BiVac Polio Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19
|
||
| Completed |
NCT03714737 -
Immunogenicity and Safety of Bivalent Meningococcal Serogroups A and C Tetanus Toxoid Conjugate Vaccine in Chinese
|
Phase 3 | |
| Completed |
NCT04664309 -
Understanding Immunity to the COVID-19 Vaccines
|